Navigation Links
Tolerx Presents Preclinical Data on Novel Anti-GITR Cancer Immunotherapeutic Demonstrating Enhanced Anti-Tumor Responses
Date:4/5/2011

eutic drugs showed potent anti-tumor activity against established tumors and were efficacious across multiple classes of drugs including alkylating agents, DNA intercalators, and pyrimidine analogs.  
  • The combination of anti-GITR and gemcitabine showed anti-tumor activity against established tumors comparable to a combination consisting of anti-CTLA4 and gemcitabine.
  • The use of a triple combination (anti-GITR, anti-CTLA4, and gemcitabine) demonstrated the greatest anti-tumor results, with complete tumor regression observed in greater than 73% of mice (P<0.01).

  • A Phase 1, first-in-human, open label, dose escalation safety study of TRX518 in adults with Stage III/IV metastatic melanoma was initiated in December 2010 and is currently underway.

    About TRX518

    TRX518 is an investigational immunotherapy designed to activate GITR (glucocorticoid-induced tumor necrosis factor receptor) found on multiple types of T cells and other immune cells. GITR plays a role in directing the anti-tumor immune response via a multifaceted mechanism of action that includes activating tumor antigen-specific T effector cells, abrogating the suppression induced by T regulatory cells, and activating NK cells. In preclinical studies, TRX518 achieved its effect without compromising normal immune function, and preclinical models suggest TRX518 to have a favorable safety profile. A Phase 1 clinical study of TRX518, a first-in-class anti-GITR monoclonal antibody, has been initiated to assess the safety, tolerability, pharmacokinetic, and pharmacodynamic profiles of ascending single doses in patients with malignant melanoma. TRX518 is designed to have activating and sustaining effects on T lymphocytes and other cells for enhancing the immune system's responses against cancer cells, including responses that may occur with TRX518 alone, as well as complementary responses in combination with other cancer therapies including cancer vaccines. <
    '/>"/>

    SOURCE Tolerx, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3

    Related biology technology :

    1. Laureate Announces Manufacturing Agreement with Tolerx
    2. Tolerx Expands Phase 3 DEFEND Trial of Otelixizumab in Europe
    3. Tolerx Announces Amendment to Phase 3 DEFEND Protocol
    4. Tolerx Presents Otelixizumab Phase 2 Dose Optimization Data At The IDFs 20th World Diabetes Congress
    5. Tolerx Initiates Phase 1 Clinical Trial of TRX518, a First-in-Class anti-GITR Antibody for the Treatment of Cancer
    6. Bluestar Silicones Presents Adhesive Gels for Wound Care at Medical Grade Polymers Conference
    7. Acologix Presents Preclinical Data on Cartilage Regeneration by AC-100 at the 30th ASBMR Annual Meeting
    8. Enobia Pharma Presents PreClinical Data Showing ENB-0040 Significantly Improved Survival and Healed Skeletal Manifestations of Severe Hypophosphatasia in Mice
    9. MedImmune Presents Data at AAP National Conference & Exhibition Demonstrating Burden of RSV Disease
    10. GeoVax Presents Data at AIDS Vaccine 2008 Conference
    11. Dendreon Presents Preclinical Data Validating Anti-Tumor Activity of D-3263, a Trp-p8 Agonist
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/11/2014)... , July 11, 2014 /PRNewswire-iReach/ -- Maxim Peptide, ... peptides that are used solely in scientific experiments, is ... successful years in business, Maxim Peptide, which was created ... launched a new and updated website that now features ... section has been updated with fascinating articles about peptide ...
    (Date:7/11/2014)... , July 11, 2014 /CNW/ - Sunovion Pharmaceuticals Canada ... TM (eslicarbazepine acetate) for use as a once-daily ... patients with epilepsy who are not satisfactorily controlled with ... use in patients under 18 years of age. ... neurological disorders and according to Epilepsy Canada, it affects ...
    (Date:7/10/2014)... UK (PRWEB) July 10, 2014 ... 21st Century Medicine Forum on ‘Commercialising Longevity Research’ ... and entrepreneurs to the London Bioscience Innovation Center ... Research Foundation and Aging Analytics Ltd. The meeting ... investment in translational research for age-related disease, as ...
    (Date:7/10/2014)... OMICS Group’s 5th International conference and ... 2014 at Double Tree by Hilton Beijing, China is ... Analytical & Bioanalytical research methods only to facilitate improved ... occasion, Dr. Srinubabu Gedela, MD of OMICS Group Inc ... remarkable one in bringing a unique and international mix ...
    Breaking Biology Technology:Maxim Peptide Celebrates Second Anniversary Online with an Updated Website and Special Deals Section 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 5DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 6A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4
    ... Pharmaceuticals, Inc., a,vertically integrated cGMP contract development ... Wood as Vice President, Business,Development. Ms. Wood ... including guiding Stason,s global business development,activities. Ms. ... experience in,sales, marketing, business and strategic planning, ...
    ... British Columbia researchers has developed a technique that controls ... superconductors, a procedure considered impossible for the past two ... the team deposited potassium atoms onto the surface of ... the scientists to continuously manipulate the number of electrons ...
    ... for Metabolic and Bariatric Surgery ... ... USGI Medical Inc. (USGI),announced today that leading experts presented clinical evidence ... an incisionless technique to reduce the size of the,gastric pouch and ...
    Cached Biology Technology:Stason Pharmaceuticals, Inc. Appoints Diana Wood as Vice President, Business Development 2UBC physicists develop 'impossible' technique to study and develop superconductors 2Studies Show USGI Medical's EndoSurgical Operating System(TM) Enables Incisionless Surgery to Reduce Gastric Pouch and Stoma After Gastric Bypass 2
    (Date:7/11/2014)... from The Chinese University of Hong Kong, BGI and ... linked to salt tolerance, with implication for improving this ... published online in Nature Communications provides an ... improvement. , Soybean is an important crop for the ... have less genetic diversities than their wild counterparts. Among ...
    (Date:7/11/2014)... other group members to reduce aggression and gain access ... for grooming activities shows a certain pattern across the ... journal Biology Letters . , Grooming between individuals ... ulterior motives. To be groomed has hygienic benefits and ... individual can provide access to infants, mating opportunities and ...
    (Date:7/11/2014)... two different ways that allow unprecedented experimental insights ... of oxygen molecules in photosynthesis. The two studies ... Nature Communications . , "The new knowledge will ... oxidation, which are key components for building artificial ... energy in fuels like hydrogen, ethanol or methanol," ...
    Breaking Biology News(10 mins):BGI reports a novel gene for salt tolerance found in wild soybean 2Baboons groom early in the day to get benefits later 2Molecular snapshots of oxygen formation in photosynthesis 2
    ... body's molecules controls the trafficking of T cells through the ... -- a crucial response that sometimes goes awry, attacking the ... control system -- composed of a fat-like compound called S1P ... cells from launching harmful reactions. But when the S1P traffic ...
    ... gene mutation that identifies the lung cancer patients most likely ... with a response to the drug cetuximab (Erbitux), according to ... the Journal of the National Cancer Institute. Both ... , Some patients with non?small-cell lung cancer (NSCLC) have mutant ...
    ... evidence that olfaction is uniquely a "dual" sense, in that ... arrives through the nose rather than the mouth. In the ... that the smell of chocolate activated different brain regions according ... through the mouth or through the nose. , In a ...
    Cached Biology News:Discovery of T-cell 'traffic control' boosts new drug promise 2Discovery of T-cell 'traffic control' boosts new drug promise 3Discovery of T-cell 'traffic control' boosts new drug promise 4Treatments have same target, different responses for lung cancer patients with genetic mutation 2Nose odors and mouth odors: The brain distinguishes 2Nose odors and mouth odors: The brain distinguishes 3
    b-Catenin (pSer675), phospho-specific...
    BDFastImmune? IFN-gamma /CD69/CD4/CD3 Storage Temperature: Refrigerate(2 to 8C)...
    PKC (pSer345), phospho-specific...
    Rabbit polyclonal to IRS1 (phospho S636) ( Abpromise for all tested applications). entrezGeneID: 3667 SwissProtID: P35568...
    Biology Products: